Heart failure has been called the “undead cancer” for many years, and its 5-year mortality rate is close to 40%, which has a great impact on patients’ quality of life and life expectancy, and is an urgent end-stage disease in the cardiovascular field. He had an acute myocardial infarction 2 years ago and has been admitted to the hospital for several heart failure episodes since then. His heart’s ejection fraction is only 30%, and he says he has difficulty breathing when lying down and has to sleep with a pillow. He has applied a variety of medications currently recommended in our heart failure guidelines, such as RAAS inhibitors, beta-blockers, aldosterone receptor antagonists, and diuretics, among others, but still has recurrent heart failure episodes with intermittent worsening dyspnea and bilateral lower extremity edema. What should we do in this situation? The latest therapeutic development in the field of heart failure is the introduction of angiotensin receptor enkephalinase inhibitors (ARNI). Nocinto is the first ARNI agent, which is a crystalline complex of sacubitril and valsartan combined in a 1:1 molar ratio. Previous studies have demonstrated that RAAS and sympathetic nervous system overactivation can promote the onset and progression of heart failure, while the ryanodine system is a new neuroendocrine system that has been newly identified to slow the progression of heart failure. The use of enkephalin inhibitors can inhibit enkephalin hydrolysis of natriuretic peptides and increase natriuretic peptide levels, thus exerting a beneficial effect on heart failure. The efficacy of this new drug is supported by large-scale evidence-based medical evidence. In the PARADIGM study, a head-to-head comparison between nocicept and enalapril, the primary endpoint of which was cardiovascular death or hospitalization for heart failure, nocicept significantly reduced the risk of cardiovascular death or hospitalization for heart failure by 20% compared to enalapril, a result that is quite encouraging. Based on the above evidence-based evidence, I gave Mr. Zhang a clinical trial of Nocinto, after 3 months of application, Mr. Zhang’s symptoms did improve significantly, dyspnea significantly reduced, daily activity tolerance also had some improvement, the key is the ejection fraction of the heart rose to 45%, this result fully confirmed that Nocinto in improving the symptoms of heart failure patients at the same time, can really improve cardiac function, and ultimately Improve the long-term prognosis of patients. We hope that in the future development of medical career, more and more new drugs will be introduced to bring benefits to patients in different fields.